Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors

被引：0
|
作者：
Puca, F. [1 ]
Fodale, V. [1 ]
Randazzo, P. [2 ]
Fabbrini, D. [2 ]
Missineo, A. [1 ]
Bisbocci, M. [3 ]
Esposito, S. [4 ]
Nibbio, M. [4 ]
Amaudrut, J. [2 ]
Colaceci, F. [5 ]
Sasso, R. [5 ]
Scalabri, F. [1 ]
Loponte, S. [1 ]
Alli, C. [3 ]
Pucci, V. [4 ]
Montalbetti, C. [2 ]
Di Fabio, R. [2 ]
Petrocchi, A. [2 ]
Carugo, A. [1 ]
Toniatti, C. [1 ]
机构：
[1] IRBM SpA, Biol, Rome, Italy
[2] IRBM SpA, Small Mol R&D, Rome, Italy
[3] IRBM SpA, Translat Res, Rome, Italy
[4] IRBM SpA, Expt Pharmacol, Rome, Italy
[5] IRBM SpA, Vivo Pharmacol, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [41] Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor
    Kato, Jun-Ya
    Korenaga, Shigeru
    Iwakura, Masaru
    SSRN, 2022,
  • [42] Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers
    Li, Wenqian
    Liu, Bin
    Wang, Junmei
    Yin, Tinggui
    Yu, Kuo-Long
    Kumar, Sanjeev
    Wen, Zhiming
    Zhao, Genshi
    Pan, Weitao
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Discovery of ellagic acid as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) for cancer treatment: In vitro and in silico study
    Ma, Chun-Hui
    Zhao, Ji-Feng
    Zhang, Xu-Guang
    Ding, Chuan-Hua
    Hao, Hui-Hui
    Ji, Ying-Hui
    Li, Li-peng
    Guo, Zhen-Tao
    Liu, Wen-Shan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 254
  • [44] SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
    Drilon, Alexander
    Sharma, Manish R.
    Johnson, Melissa L.
    Yap, Timothy A.
    Gadgeel, Shirish
    Nepert, Dale
    Feng, Gang
    Reddy, Micaela B.
    Harney, Allison S.
    Elsayed, Mohamed
    Cook, Adam W.
    Wong, Christina E.
    Hinklin, Ronald J.
    Jiang, Yutong
    Brown, Eric N.
    Neitzel, Nickolas A.
    Laird, Ellen R.
    Wu, Wen -, I
    Singh, Anurag
    Wei, Ping
    Ching, Keith A.
    Gaudino, John J.
    Lee, Patrice A.
    Hartley, Dylan P.
    Rothenberg, S. Michael
    CANCER DISCOVERY, 2023, 13 (08) : 1789 - 1801
  • [45] FCN-159: A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors
    Shu Lin
    Zhao, Xingdong
    Zhou, Zuwen
    Tan, Haohan
    Ling Chen
    Rui Tan
    Zhang, Weipeng
    Jiang, Lihua
    Li Linghu
    Jing Sun
    Zhou, Jiashu
    Te Li
    Song, Yunlong
    Wang, Weibo
    CANCER RESEARCH, 2020, 80 (16)
  • [46] A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors
    Drilon, Alexander E.
    Johnson, Melissa Lynne
    Gadgeel, Shirish M.
    Nepert, Dale
    Feng, Gang
    Golmakani, Marzieh
    Reddy, Micaela
    Harney, Allison
    Oliver, Colleen
    Mills, Bethany
    Therond, Judy
    Rothenberg, S. Michael
    Sharma, Manish
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers
    Irie, Takayuki
    Asami, Tokiko
    Sawa, Ayako
    Uno, Yuko
    Taniyama, Chika
    Funakoshi, Yoko
    Masai, Hisao
    Sawa, Masaaki
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14153 - 14164
  • [48] Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
    Brana, Irene
    Shapiro, Geoffrey
    Johnson, Melissa Lynne
    Yu, Helena Alexandra
    Robbrecht, Debbie
    Tan, Daniel Shao-Weng
    Siu, Lillian L.
    Minami, Hironobu
    Steeghs, Neeltje
    Hengelage, Thomas
    Tan, Eugene
    Biette, Kelly
    Xu, Kun
    Moody, Susan Elizabeth
    Jove, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis
    Singh, Pooja
    Kumar, Vikas
    Lee, Keun Woo
    Hong, Jong Chan
    PHARMACEUTICALS, 2024, 17 (07)
  • [50] Identification of a potent, orally bioavailable and selective MCT4 Inhibitor for the treatment of solid Warburg tumors
    Hambruch, Nina
    Herkert, Barbara
    Gege, Christian
    Mallinger, Aurelie
    Fabian, Johannes
    Kinzel, Olaf
    Wang, Yansong
    Fink, Gero
    Albers, Michael
    Funk, Anette
    Bittman-Waetzig, Annika
    Fleckenstein, Tilly
    Braun, Floriane
    Kremoser, Claus
    CANCER RESEARCH, 2019, 79 (13)
12345